Implementing Pharmaceutical Serialization Across a Diverse Manufacturing Environment, Part 1 – Full Article Published in Manufacturing Chemist
Posted on February 8, 2017 by Helena Graham
The US and European healthcare industry is changing rapidly, with organisations facing the challenge of adopting new regulations for pharmaceutical serialization.
With the deadlines for companies to implement track and trace processes firmly on the horizon, manufacturers should be considering the best approach to implement new pharmaceutical serialization solutions in time.
In a piece for Manufacturing Chemist , Carlos Machado, serialization director at Zenith Technologies explores the challenges linked to pharmaceutical serialization strategies and deployment and the benefits that can be gained from taking a proactive approach to implementation.
See the results of our recent poll survey where we asked – What is the biggest issue you face when implementing serialization (Survey of 100 pharmaceutical manufacturing professional) >>
Statistics show that globally counterfeit drugs sales have reached $75 billion annually and the World Health Organisation (WHO) reports that 16 per cent of counterfeit drugs contain the wrong ingredients, indicating the seriousness of the falsified medicines crisis. It is statistics like these that have been a key driver for change within the industry.
With pharmaceutical serialization compliance requirements having already been implemented in parts of the globe including China, India, South Korea and Saudi Arabia, the US and the EU are quick to follow, with deadlines in 2017 and 2019 respectively.
Carlos explains the steps that pharmaceutical manufacturers should take in order to remain compliant, including understanding the scope and impact of the project, as well as having a defined project plan in place.
To read more on how pharmaceutical manufacturers can prepare for serialization, read the full article here.
Part two of the article will be featured in the March issue of Manufacturing Chemist.